ClinicalTrials.gg
Not yet recruitingNCT06894693Updated Mar 25, 2025

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

A Phase 1 interventional study of RS001 injection in B-cell Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia, sponsored by Guangdong Ruishun Biotech Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Guangdong Ruishun Biotech Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).

Read the detailed description

CD19-positive relapsed/refractory B-cell malignancies (including B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia).

02

Conditions studied

  • B-cell Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia
03

In context

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

This study's planned enrollment of 13 is below the median of 34 across 775 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

Guangdong Ruishun Biotech Co., Ltd is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign an ICF and expect to complete the subsequent follow-up.
  2. Aged 18 to 75 years (including cut-offs), regardless of gender.
  3. Meet one of the following B-cell :

<!-- -->

  1. . B-cell non-Hodgkin's lymphoma diagnosed as CD19-positive by cytology or histopathology according to WHO 2022 criteria, including confirmed (1) diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS); (2) follicular lymphoma histopathologically graded as grade 3b (FL3b); (3) follicular lymphoma with diffuse large B-cell transformation; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) high-grade B-cell lymphoma (HGBCL).

    1. B-cell non-Hodgkin lymphoma, defined as meeting one or more of the following criteria:

      • Definition of relapse: Relapse after achieving remission (PR and CR) with or higher therapy;
      • Definition of refractory: No response to second-line or more therapy: The best efficacy of last therapy is PD or SD (SD requires at least 2 cycles of treatment); Recurrence (must have -proven recurrence) or progression within 12 months of stem cell transplantation (ASCT) . If salvage therapy, no response to last therapy (SD or PD).
    2. Subjects must have received adequate treatment in the past, which should include the following treatments:

      • Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative;
      • Chemotherapy containing anthracycline drugs;
      • For subjects with transformed follicular lymphoma (tFL) who have been previously treated with follicular lymphoma (FL) chemotherapy and with transformation to DLBCL show refractory to chemotherapy.
    3. performance status 0 to 1.
    4. The presence of a that meets one of the following criteria:

      • The long axis of the lymph node lesion exceeds 15 mm in length (the short axis is measurable);
      • The long and short axes of the extralymph node lesion exceed 10 mm in length.
  2. Relapsed/refractory B-cell acute lymphoblastic leukemia must meet the following requirements:

    1. Relapsed: Recurrence within 12 months after the first remission;
    2. Refractory: i. failure to remit after more than 6 weeks of induction therapy or failure to remit after two courses of induction therapy; ii. relapse after 2 or more CRs; iii. first relapse after chemotherapy and failure to remit after having received at least 1 salvage therapy; iv. relapse after autologous hematopoietic stem cell transplantation;
    3. Prior to screening, leukemia cells expressing CD19 are detectable in bone marrow or peripheral blood.
    4. Ph+ ALL patients who have failed treatment with at least 2 tyrosine kinase inhibitor (TKI) drugs (including at least 1 2nd generation TKI drug) or are intolerant of drug-related side effects such as allergy to components of the TKI class of drugs, blood abnormalities, liver or kidney impairment, severe cardiovascular toxicity, and other drug-related side effects that prevent them from continuing to be a user; If the patient has the T315I mutation, TKI salvage therapy is not required;
    5. The proportion of primitive and naïve lymphocytes in bone marrow during the screening period ≥5%; 4. Laboratory results within 7 days prior to Lymphodepletion need to meet the following criteria:

    <!-- -->

    1. Coagulation function:

      • ≤ 1.5 times the (ULN);
      • Prothrombin time (PT) ≤ 1.5 times ULN;
    2. Liver function:

      • Glutathione aminotransferase () ≤ 5 times the upper limit of normal (ULN);
      • Total ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome;
      • Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included.
    3. Renal function: Serum creatinine ≤ 1.5 times ULN or a ≥ 60 ml/min;
    4. Complete blood count (No blood transfusion treatment received within 7 days prior to examination):

      • ≥ 80 g/L;
      • (ANC) ≥ 1.0 x 10\^9/L;
      • A count ≥ 50 x 10\^9/L;
    5. Cardiopulmonary function:

      • (LVEF) ≥ 45%;
      • Oxygen saturation ≥ 91%; 5. Female subjects with of should have a negative pregnancy test during the screening period. Any male and female subjects of childbearing potential must agree to use an effective method for at least six months from the time that they sign the form until the end of the cell infusion. Female subjects without childbearing potential (meeting at least 1 of the following criteria) is described below:

    a. Have undergone a hysterectomy or bilateral oophorectomy; b. Medically recognised ovarian failure; c. Medically recognised as (at least 12 consecutive months of menopause without pathological or physiological cause).

Exclusion criteria

Exclusion Criteria:

  1. Other within 5 years prior to screening, except adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, post-radical localized prostate cancer, post-radical ductal carcinoma in situ, and post-radical thyroid cancer;
  2. Any unstable systemic disease: including but not limited to active infection (other than local infection), unstable angina, cerebrovascular accident or transient ischaemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), class III or IV cardiac insufficiency, hypertension (refractory hypertension is defined as blood pressure that has not reached standard after >1 month of reasonably tolerable treatment with ≥3 antihypertensive drugs (including diuretics) at adequate doses based on lifestyle improvement or blood pressure that is not effectively controlled with ≥4 antihypertensive drugs), severe cardiac arrhythmias requiring pharmacologic treatment, hepatic arrhythmias, liver diseases, kidney diseases or metabolic disorders;
  3. Patients with B-cell non-Hodgkin's lymphoma with active central nervous system invasion.
  4. Patients with positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titres not within the normal reference range, positive virus (HCV) antibody and peripheral blood HCV RNA ,positive for (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test.
  5. Subjects who are receiving systemic prior to screening and who are judged by the investigator to require long-term treatment with systemic steroids during the treatment period (except for inhaled or topical use).
  6. Previous organ transplantation or preparation for organ transplantation (except for haematopoietic stem cell transplantation).
  7. Persons with acute/chronic Graft-vs-Host Disease (GvHD).
  8. Patients have received a haematopoietic stem cell transplant within 2 months prior to screening.
  9. Patients who have previously received any CD19-CAR-T/NK cell therapy, or received CAR-T/NK cell therapy targeting other antigens within the three months prior to screening.
  10. Active neurological or inflammatory diseases (e.g. Guillain-Barre Syndrome (GBS), Amyotrophic lateral sclerosis (ALS)).
  11. active cerebrovascular diseases (such as cerebral edema, posterior reversible encephalopathy syndrome).
  12. Patients with a of less than 3 months.
  13. Participants who have previously been involved in other interventional clinical studies and received active drugs, with the last use of an unapproved new drug being less than 28 days prior to signing the for this trial, or the last use of an approved drug being less than five half-lives prior to cell infusion.
  14. Received attenuated within 6 weeks prior to lymphodepletion.
  15. The subjects have or reactions to fludarabine, cyclophosphamide, tocilizumab, investigational product and its ingredients.
  16. Remaining within the of other antitumor treatments prior to lymphodepletion.
  17. Patients who, in the investigator's judgment and/or clinical criteria, have a contraindication to any of the study procedures or have other medical conditions that may place them at unacceptable risk.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    RS001 injection

    The trial is divided into two parts: Part A is a dose escalation trial with three dose groups (5×10\^6 CAR+ cells/kg, 1×10\^7 CAR+ cells/kg and 2×10\^7 CAR+ cells/kg at day 0), with 7-18 patients planned to be enrolled. Part B is a dose-expansion trial in which 6\~12 patients will receive RS001 infusions at RP2D dose levels.

    Biological: RS001 injection

Interventions

  • BiologicalRS001 injection

    CD19-CAR-mbIL15-DNT Cells.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT)

    To evaluate the safety, tolerability, and determine the recommended dosage of RS001 for BCM subjects.

    Time frame: Up to 28 days

  2. Maximum Tolerated Dose (MTD)

    MTD is the highest dose for DLT in ≤1/6 subjects.

    Time frame: Up to 28 days

  3. Incidence of abnormalities

    Incidence of abnormalities in AE/SAE/AESI/laboratory tests/electrocardiograms/vital signs.

    Time frame: Up to 28 days

Secondary outcomes

  1. Pharmacokinetics (PK) indicator (Cmax)

    The peak concentration of CD19-CAR-mbIL15-DNT cells amplified in the peripheral blood (Cmax, detected by qPCR or Flow Cytometry).

    Time frame: Up to 90 days

  2. Pharmacokinetics (PK) indicator (AUC)

    CD19-CAR-mbIL15-DNT cells blood concentrations will be measured at different time points to evaluate the area under the curve (AUC). (AUC, detected by qPCR or Flow Cytometry).

    Time frame: Up to 90 days

  3. Pharmacokinetics (PK) indicator (Tmax)

    CD19-CAR-mbIL15-DNT cells blood concentrations will be measured at different time points to evaluate the peak plasma time (Tmax). Tmax is defined as the time to reach the highest concentration (Tmax, detected by qPCR or Flow Cytometry).

    Time frame: Up to 90 days

  4. Pharmacokinetics (PK) indicator (T1/2)

    CD19-CAR-mbIL15-DNT cells blood concentrations will be measured at different time points to evaluate the elimination half-life in hours (T1/2). T1/2 is defined as the time point when the concentration of CD19-CAR-mbIL15-DNT reaches half of maximum in a patient's peripheral blood (T1/2, detected by qPCR or Flow Cytometry).

    Time frame: Up to 90 days

  5. Overall Response Rate

    Objective response rates (ORR; complete response \[CR\] + partial response \[PR\]) in B-NHL subjects and composite complete remission rates (CRc; CR + CR with incomplete hematologic recovery \[CRi\]) in ALL subjects were assessed using Lugano 2014 criteria / LYRIC Criteria (2016) and National Comprehensive Cancer Network (NCCN) guidelines (v3.2025), respectively.

    Time frame: Up to 2 years

  6. Disease Control Rate

    The percentage of PR, CR and SD patients in the total B-NHL patient population.

    Time frame: Up to 2 years

  7. Duration of Response

    The time from the start of the first assessment of CR or PR to the first assessment as disease recurrence or progression or death in B-NHL subjects. The time from the first assessment of the tumor for CR or CRi to the first assessment of disease recurrence or death from any cause in B-ALL subjects.

    Time frame: Up to 2 years

  8. Progression Free Survival

    The time from the first cell infusion to the first evaluation of tumor progression or death from any cause in B-NHL subjects.

    Time frame: Up to 2 years

  9. Overall Survival

    From the date of entry into the clinical study until death from any cause

    Time frame: Up to 2 years

  10. Overall Response Rate at 3 months

    The percentage of PR and CR patients in B-NHL patient population at 3 months.

    Time frame: Up to 3 months

  11. Relapse-Free Survival

    Evaluate only ALL patients who achieved CR or CRi. This refers to the period from the first assessment of CR or CRi until the first evaluation indicating disease relapse or death from any cause during CR or CRi.

    Time frame: Up to 2 years

  12. Event-Free Survival

    This is used for evaluating all ALL subjects. The period starts from the first infusion of RS001 injection until treatment failure, relapse, or death (any cause), whichever occurs first. For subjects without these events, the timeframe will be calculated up to the date of the last follow-up visit. For patients who did not achieve CR or CRi, EFS will be calculated from the clinical trial enrollment date until disease progression or death, with the first occurring event being considered as the endpoint.

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.

Of 91 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 12 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 25, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2028
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06894693
Lead sponsor
Guangdong Ruishun Biotech Co., Ltd
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Mar 25, 2025

Study contacts

JunYuan Qi, MD, PHD
Contact
qijy@ihcams.ac.cn
18622662361
JunYuan Qi, MD, PHD
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion